Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX NASDAQ:MOR NASDAQ:RLAY NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$70.79+0.8%$68.59$1.16▼$14.10$3.07B-0.12189,291 shs1.56 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARLAYRelay Therapeutics$15.88$14.25$3.03▼$17.47$3.04B1.753.88 million shs10.74 million shsSANASana Biotechnology$3.15$3.20$2.58▼$6.55$876.62M2.143.94 million shs6.74 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics+0.54%+4.40%+5.03%+18.66%+40.28%MORMorphoSys0.00%0.00%0.00%0.00%0.00%RLAYRelay Therapeutics+2.06%+11.52%+31.57%+60.24%+372.62%SANASana Biotechnology+3.62%+13.72%+2.94%+1.29%+14.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$70.79+0.8%$68.59$1.16▼$14.10$3.07B-0.12189,291 shs1.56 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARLAYRelay Therapeutics$15.88$14.25$3.03▼$17.47$3.04B1.753.88 million shs10.74 million shsSANASana Biotechnology$3.15$3.20$2.58▼$6.55$876.62M2.143.94 million shs6.74 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics+0.54%+4.40%+5.03%+18.66%+40.28%MORMorphoSys0.00%0.00%0.00%0.00%0.00%RLAYRelay Therapeutics+2.06%+11.52%+31.57%+60.24%+372.62%SANASana Biotechnology+3.62%+13.72%+2.94%+1.29%+14.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/AMORMorphoSys 0.00N/AN/AN/ARLAYRelay Therapeutics 3.00Buy$23.3046.73% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50201.59% UpsideCurrent Analyst Ratings BreakdownLatest SANA, GMTX, MOR, and RLAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026RLAYRelay Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $26.005/26/2026RLAYRelay Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $28.005/20/2026RLAYRelay Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/20/2026RLAYRelay Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $27.005/20/2026RLAYRelay Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $21.005/19/2026RLAYRelay Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.005/19/2026RLAYRelay Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy5/19/2026RLAYRelay Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/19/2026RLAYRelay Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$23.00 ➝ $26.005/11/2026SANASana Biotechnology Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.005/1/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17RLAYRelay Therapeutics$15.35M198.21N/AN/A$3.27 per share4.86SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ARLAYRelay Therapeutics-$276.48M-$1.57N/AN/AN/AN/A-43.94%-40.11%8/6/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)Latest SANA, GMTX, MOR, and RLAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49MORMorphoSys4.981.381.38RLAYRelay TherapeuticsN/A22.1322.13SANASana BiotechnologyN/A1.291.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%MORMorphoSys18.38%RLAYRelay Therapeutics96.98%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%MORMorphoSys0.05%RLAYRelay Therapeutics5.04%SANASana Biotechnology25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableRLAYRelay Therapeutics330191.59 million181.93 millionOptionableSANASana Biotechnology380278.29 million207.61 millionOptionableSANA, GMTX, MOR, and RLAY HeadlinesRecent News About These CompaniesHarbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific AdvisorJune 12, 2026 | finance.yahoo.comAs the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?June 10, 2026 | msn.comSana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comSana Biotechnology Shareholders Reelect Directors and Ratify AuditorJune 5, 2026 | tipranks.comDid Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?June 2, 2026 | prnewswire.comSana Biotechnology to Present at June 2026 Investor ConferencesMay 27, 2026 | globenewswire.comSana Biotechnology Raises $69 Million Through Equity OfferingMay 15, 2026 | tipranks.comSana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market FacilityMay 15, 2026 | marketwatch.comSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) FacilityMay 15, 2026 | globenewswire.comSana Biotechnology (SANA) Receives a Buy from WedbushMay 14, 2026 | theglobeandmail.comBank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)May 13, 2026 | theglobeandmail.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell ...May 13, 2026 | markets.businessinsider.comSana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsMay 12, 2026 | globenewswire.comSana: Q1 Earnings SnapshotMay 12, 2026 | finance.yahoo.comSana Biotechnology Reports First Quarter 2026 Financial Results and Business UpdatesMay 12, 2026 | markets.businessinsider.comSana Biotechnology to Present at the BofA Securities 2026 Healthcare ConferenceMay 5, 2026 | globenewswire.comSana to present in vivo CAR T data as Janux drops trialApril 28, 2026 | msn.comSana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingApril 27, 2026 | globenewswire.comSana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 DiabetesApril 27, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Micron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026SANA, GMTX, MOR, and RLAY Company DescriptionsGemini Therapeutics NASDAQ:GMTX$70.79 +0.58 (+0.83%) As of 06/18/2026Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 06/18/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Relay Therapeutics NASDAQ:RLAY$15.88 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$16.21 +0.33 (+2.08%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Sana Biotechnology NASDAQ:SANA$3.15 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.11 -0.04 (-1.14%) As of 06/18/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
